|Other Names||Complement decay-accelerating factor, CD55, CD55, CR, DAF|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||This protein recognizes C4b and C3b fragments that condense with cell-surface hydroxyl or amino groups when nascent C4b and C3b are locally generated during C4 and c3 activation. Interaction of daf with cell-associated C4b and C3b polypeptides interferes with their ability to catalyze the conversion of C2 and factor B to enzymatically active C2a and Bb and thereby prevents the formation of C4b2a and C3bBb, the amplification convertases of the complement cascade.|
|Cellular Location||Isoform 1: Cell membrane; Single-pass type I membrane protein Isoform 3: Secreted Isoform 5: Secreted Isoform 7: Cell membrane; Lipid-anchor, GPI-anchor|
|Tissue Location||Expressed on the plasma membranes of all cell types that are in intimate contact with plasma complement proteins. It is also found on the surfaces of epithelial cells lining extracellular compartments, and variants of the molecule are present in body fluids and in extracellular matrix|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a protein involved in the regulation ofthe complement cascade. The encoded glycoprotein is also known asthe decay-accelerating factor (DAF); binding of DAF to complementproteins accelerates their decay, disrupting the cascade andpreventing damage to host cells. Antigens present on the DAFglycoprotein constitute the Cromer blood group system (CROM). Twoalternatively spliced transcripts encoding different proteins havebeen identified. The predominant transcript encodes amembrane-bound protein expressed on cells exposed to plasmacomponent proteins but an alternatively spliced transcript producesa soluble protein present at much lower levels. Additional,alternatively spliced transcript variants have been described, buttheir biological validity has not been determined. [provided byRefSeq].
Romero, R., et al. Am. J. Obstet. Gynecol. 203 (4), 361 (2010) :Gustafsson, D.J., et al. Virology 405(2):474-482(2010)Alegretti, A.P., et al. Cell. Immunol. 265(2):127-132(2010)Kim, Y., et al. Ann. Clin. Lab. Sci. 40(3):226-232(2010)Storry, J.R., et al. Transfusion 43(3):340-344(2003)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.